|

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

RECRUITINGSponsored by National Cancer Institute (NCI)
Actively Recruiting
SponsorNational Cancer Institute (NCI)
Started2014-03-25
Est. completion2100-01-01
Eligibility
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT02610426

Summary

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* European American patients with DNA available
* European American patients who developed CHF and patients who did not develop CHF following a full course of treatment with an anthracycline and bevacizumab
* African American cases (based on a drop in left ventricular ejection fraction \[LVEF\] \< 50 or a drop from baseline \> 20 points) and African American controls

Conditions4

Breast CancerBreast CarcinomaCancerHeart Disease

Locations1 site

Eastern Cooperative Oncology Group
Boston, Massachusetts, 02215
Bryan P. Schneider317-274-6473bpschnei@iupui.edu

Browse More Trials

Cancer trialsHeart Disease trialsBreast Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.